Cargando…
Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice
BACKGROUND: Potassium channel tetramerisation domain containing 9 (KCTD9), a member of KCTD family with a DNA-like pentapeptide repeat domain, was found to be increased particularly in NK cells of patients with HBV-induced acute-on-chronic liver failure (HBV-ACLF) and experimental viral fulminant he...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019787/ https://www.ncbi.nlm.nih.gov/pubmed/29940856 http://dx.doi.org/10.1186/s12865-018-0256-x |
_version_ | 1783335182362738688 |
---|---|
author | Zhang, Xiaoping Zhu, Lin Zhou, Yaoyong Shi, Aichao Wang, Hongwu Han, Meifang Wan, Xiaoyang Kilonzo, Semvua Bukheti Luo, Xiaoping Chen, Tao Ning, Qin |
author_facet | Zhang, Xiaoping Zhu, Lin Zhou, Yaoyong Shi, Aichao Wang, Hongwu Han, Meifang Wan, Xiaoyang Kilonzo, Semvua Bukheti Luo, Xiaoping Chen, Tao Ning, Qin |
author_sort | Zhang, Xiaoping |
collection | PubMed |
description | BACKGROUND: Potassium channel tetramerisation domain containing 9 (KCTD9), a member of KCTD family with a DNA-like pentapeptide repeat domain, was found to be increased particularly in NK cells of patients with HBV-induced acute-on-chronic liver failure (HBV-ACLF) and experimental viral fulminant hepatitis. Knockdown of KCTD9 in immortalized NK cells inhibits cytokines production and cytotoxicity. As NK cell activation was shown to exacerbate liver damage in viral fulminant hepatitis, we propose that target inhibition of KCTD9 may prohibit NK cells activity and thus ameliorate liver damage in viral fulminant hepatitis. RESULT: Hydrodynamic delivery of plasmid expressing short-hairpin RNA against KCTD9 resulted in impaired NK cells function as demonstrated by reduced cytokine production and cytotoxicity, and ameliorated liver injury as manifested by improved liver histology and survival rate. In contrast, delivery of plasmid expressing KCTD9 led to deteriorated disease progression. CONCLUSION: Interference with KCTD9 expression exert beneficial effect in viral fulminant hepatitis therapy. Such effect may be mediated by impairment of NK cell activation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12865-018-0256-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6019787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60197872018-07-06 Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice Zhang, Xiaoping Zhu, Lin Zhou, Yaoyong Shi, Aichao Wang, Hongwu Han, Meifang Wan, Xiaoyang Kilonzo, Semvua Bukheti Luo, Xiaoping Chen, Tao Ning, Qin BMC Immunol Research Article BACKGROUND: Potassium channel tetramerisation domain containing 9 (KCTD9), a member of KCTD family with a DNA-like pentapeptide repeat domain, was found to be increased particularly in NK cells of patients with HBV-induced acute-on-chronic liver failure (HBV-ACLF) and experimental viral fulminant hepatitis. Knockdown of KCTD9 in immortalized NK cells inhibits cytokines production and cytotoxicity. As NK cell activation was shown to exacerbate liver damage in viral fulminant hepatitis, we propose that target inhibition of KCTD9 may prohibit NK cells activity and thus ameliorate liver damage in viral fulminant hepatitis. RESULT: Hydrodynamic delivery of plasmid expressing short-hairpin RNA against KCTD9 resulted in impaired NK cells function as demonstrated by reduced cytokine production and cytotoxicity, and ameliorated liver injury as manifested by improved liver histology and survival rate. In contrast, delivery of plasmid expressing KCTD9 led to deteriorated disease progression. CONCLUSION: Interference with KCTD9 expression exert beneficial effect in viral fulminant hepatitis therapy. Such effect may be mediated by impairment of NK cell activation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12865-018-0256-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-25 /pmc/articles/PMC6019787/ /pubmed/29940856 http://dx.doi.org/10.1186/s12865-018-0256-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhang, Xiaoping Zhu, Lin Zhou, Yaoyong Shi, Aichao Wang, Hongwu Han, Meifang Wan, Xiaoyang Kilonzo, Semvua Bukheti Luo, Xiaoping Chen, Tao Ning, Qin Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title | Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title_full | Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title_fullStr | Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title_full_unstemmed | Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title_short | Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice |
title_sort | interference with kctd9 inhibits nk cell activation and ameliorates fulminant liver failure in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019787/ https://www.ncbi.nlm.nih.gov/pubmed/29940856 http://dx.doi.org/10.1186/s12865-018-0256-x |
work_keys_str_mv | AT zhangxiaoping interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT zhulin interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT zhouyaoyong interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT shiaichao interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT wanghongwu interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT hanmeifang interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT wanxiaoyang interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT kilonzosemvuabukheti interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT luoxiaoping interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT chentao interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice AT ningqin interferencewithkctd9inhibitsnkcellactivationandamelioratesfulminantliverfailureinmice |